Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KG3R
|
|||
| Former ID |
DNAP001688
|
|||
| Drug Name |
Rivaroxaban
|
|||
| Synonyms |
XARELTO (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Deep vein thrombosis [ICD-11: BD71; ICD-10: I80-I82, I80.2] | Approved | [1], [2] | |
| Company |
Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H18ClN3O5S
|
|||
| Canonical SMILES |
C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
|
|||
| InChI |
1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
|
|||
| InChIKey |
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
|
|||
| CAS Number |
CAS 366789-02-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14856850, 15279667, 22395270, 24164597, 45622373, 46513422, 51091428, 52936629, 56373953, 57373622, 71825413, 87225360, 87557471, 91615930, 93580340, 99444948, 103469795, 109693118, 126659499, 126666963, 134342998, 134358083, 135213418, 135684125, 136375511, 136920411, 137128738, 139479843, 152258851, 152344334, 160645892, 160647701, 160969514, 162172236, 164045359, 164194090, 164824489, 165245531, 170498903, 171578894, 172091286, 174477515, 175266472, 175427064, 175610897, 177748765, 178103004, 180189087, 185985285, 198991713
|
|||
| ChEBI ID |
CHEBI:68579
|
|||
| ADReCS Drug ID | BADD_D01954 | |||
| SuperDrug ATC ID |
B01AF01
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor Xa (F10) | Target Info | Modulator | [3] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | ||||
| Gamma-carboxylation of protein precursors | ||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6388). | |||
| REF 2 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.